Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

CymaBay Shelves NASH Drug Seladelpar On Liver Safety Concerns

Nov 25 2019

• By Joseph Haas

Histology readings showed unexpected safety signals in CymaBay's Phase IIb NASH trial

Related Content

CymaBay Alters NASH Hypothesis After Phase IIb Failure In Hepatic Fat Reduction

Jun 11 2019

NASH Companies Take The Stage At AASLD

Nov 15 2019

Genfit Thinks Intercept’s Lead In NASH Not As Wide As Perceived

Oct 17 2019

Intercept’s NASH NDA Positions OCA For May 2020 Approval, Then Launch

Sep 30 2019

CymaBay Following The Leaders, Pursues NASH, PBC Simultaneously

Apr 16 2019

Related Companies

CymaBay Therapeutics, Inc.

Genfit SA

Intercept Pharmaceuticals, Inc.

Inventiva S.A.

Coherus Oncology, Inc.

Zydus Lifesciences Limited

T3D Therapeutics, Inc.

Additional Topics

Clinical Trials Drug Safety Research & Development Liver & Hepatic BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window